Antithrombin Market By Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Antithrombin Market
Antithrombin Market Analysis: By Application (Dry Chemistry, Biosensors, Immunoassays, Monoclonal and Polyclonal antibodies, Chromogenic Substrates, DNA Probes, Microcomputers, Automation, Robotics, Artificial Intelligence & Others) – With Forecast (2016-2021)
Report Code : HCR 0146
Updated Date: 24 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Antithrombin– Market Overview
2. Executive Summary 
3. Antithrombin– Market Landscape 
   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Antithrombin– Market Forces
   4.1. Market Drivers 
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the Antithrombin Market 
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers 
      4.4.3. Threat of New Entrants 
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. Antithrombin Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis 
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Antithrombin Market– By Application
   6.1. Dry Chemistry
   6.2. Biosensors
   6.3. Immunoassays
   6.4. Monoclonal and Polyclonal antibodies
   6.5. Chromogenic Substrates
   6.6. DNA Probes
   6.7. Microcomputers
   6.8. Automation
   6.9. Robotics
   6.10. Artificial Intelligence 
   6.11. Others
7. Antithrombin Market– By Geography
   7.1. Introduction
   7.2. Global Study
   7.3. Americas
      7.3.1. North America 
      7.3.2. Brazil
      7.3.3. Argentina
      7.3.4. Others 
   7.4. Europe
      7.4.1. U.K.
      7.4.2. France
      7.4.3. Germany
      7.4.4. Others
   7.5. APAC
      7.5.1. China
      7.5.2. Japan
      7.5.3. India
      7.5.4. Others
   7.6. ROW
8. Antithrombin Market Entropy
   8.1. New Product Launches
   8.2. M&As, Collaborations, JVs and Partnerships
9. Company Profiles 
   9.1. Abbott Laboratories
   9.2. Thermo Fisher Scientific Inc.
   9.3. Siemens AG
   9.4. Dickinson and Company
   9.5. Sysmex Corporation
   9.6. Trinity Biotech Plc
   9.7. Becton
   9.8. Beckman Coulter Inc.
   9.9. American Diagnostica GmbH
   9.10. Axis-Shield Plc
   9.11. Ovation Pharmaceuticals Inc.
   9.12. rEVO Biologics
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix
   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
Antithrombin, also known as Antithrombin III is a protien present in human blood that acts as an anticoagulant or blood thinner. The presence of antithrombin in the blood stream is extremely critical as it helps to prevent clotting of blood. Defeciency or low levels of antithrombin can lead to higher rate of clotting and excess of antithrombin can result in excessive bleeding. Thrombosis is a medical condition resulting from a low level of antithrombin that results in the obstruction of blood flow owing to the clots formed in the blood vessels. These clots can sometimes form even in the absence of an injury and also have the tendency to break free and travel through the blood vessels. This condition is known as thromboembolism.

There are two types of antithrombin defeciencies, namely, type I and type II. Inadequate amount of antithrombin is called type I and type II is associated with normal levels of antithrombin but reduced activity levels in case of affected patients’ blood. Blood clotting is associated with symptoms such as fainting, swollen legs or feet, increased heart rate, shortness of breath, among others. Antithrombin defenciency could either be acquired or inherited. Inherited antithrombin defeciency is a rare occurrence and only a maximum of 0.2% of the population has it. One of the most popular drugs for treatment of antithrombin defeciency available on the market is ATryn, developed by rEVO Biologics and received the FDA approval in 2009. 

Antithrombin Market 

In terms of applications, the Antithrombin market has been segmented across the following:
  • Dry Chemistry
  • Biosensors
  • Immunoassays
  • Monoclonal and Polyclonal antibodies
  • Chromogenic Substrates
  • DNA Probes
  • Microcomputers 
  • Automation
  • Robotics
  • Artificial Intelligence 
  • Others

Asia Pacific is expected to exhibit the highest growth rate in the antrithrombin market throughout the forecast period considered in this report. This is attributed to the increasing population in this region. However, in terms of market share, North America and Europe account for the largest share and will maintain this position till the end of the forecast period. 

The market has been segmented based on the following geographies:
  • North America
  • South America
  • APAC
  • Europe
  • Middle East 
  • Africa

A significant amount of consolidation has been taking placed in the global antithrombin market.

Sample Companies Profiled in this Report are: 
  • Thermo Fisher Scientific Inc
  • Abott Laboratories
  • Siemens AG
  • American Diagnostica GmbH 
  • Trinity Biotech
  • 10+
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports